EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 Years of European Collaboration in New Drug Development for Breast Cancer

Author： EORTC-IDBBC Awada A. Van Vreckem A. Paridaens R. Bruning P.F. Klijn J. Tomiak E. Vinholes J. Roy J.A. Kusenda Z. Hoctin Boes G. Van Glabbeke M. Piccart M.J.

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.33, Iss.8, 1997-07, pp. : 1173-1176

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

By Awada A. Biganzoli L. Cufer T. Beex L. Lohrisch C. Batter V. Hamilton A. Nooij M. Piccart M.

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 773-778

Elsevier

Access to resources Recommend Favorite

The Value of Genomic Analysis of Breast Cancer in Drug Development

By Szekely Borbala Pusztai Lajos

Journal of the National Cancer Institute Monographs, Vol. 2011, Iss. 43, 2011-10 ,pp. : 60-62

Oxford University Press

Access to resources Recommend Favorite

Drug resistance in chemotherapy for breast cancer

By Saeki Toshiaki Tsuruo Takashi Sato Wakao Nishikawsa Kiyoshiro

Cancer Chemotherapy and Pharmacology, Vol. 56, Iss. 1, 2005-11 ,pp. : 84-89

Springer Publishing Company

Access to resources Recommend Favorite

Side population cells and drug resistance in breast cancer

Molecular Medicine Reports, Vol. 11, Iss. 6, 2015-01 ,pp. : 4297-4302

Spandidos Publications

Access to resources Recommend Favorite

Breast Cancer Prevention: The Risks and Benefits of Drug Therapy

By Kaklamani V.G. O'Regan R.M.

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 173-178

Adis International

Access to resources Recommend Favorite